LOGIN  |  REGISTER
Compass Therapeutics

Varex Imaging Management to Participate in Upcoming Investor Conferences

May 28, 2024 | Last Trade: US$14.24 0.49 -3.33

SALT LAKE CITY / May 28, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences.

  • Jefferies Global Healthcare Conference in New York – June 6, 2024 at 9:00am ET
  • Goldman Sachs 45th Annual Global Healthcare Conference in Miami – June 10, 2024 (1x1 only)
  • Sidoti June 2024 Virtual Small Cap Conference – June 13, 2024 at 10:45am ET

These events can be accessed at the Varex Imaging website: www.vareximaging.com/news on the dates and times listed above.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB